Nephrology Times Commentary
From the Chair
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
From the Field
It is important to understand the challenges Medicare Advantage plans present for ESRD care.
Critical Financial Shifts Ahead: How CY 2025 ESRD PPS Changes Could Impact Small Dialysis Facilities
Sarah Tolson reviews the key financial implications of the CMS proposed rule for the ESRD Prospective Payment System.
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.